Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Khalid Saja(East Suffolk and North Essex NHS Foundation Trust), Lori A. Leslie(Hackensack University Medical Center), Alan P Skarbnik(Novant Health), Tatyana Feldman(Hackensack University Medical Center), Richard R. Furman(Cornell University), Elise A. Chong(Hospital of the University of Pennsylvania), Rosemary Harrup(Royal Hobart Hospital), Dominic LaBella(Indiana University Health), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Lia Palomba(Memorial Sloan Kettering Cancer Center), Harriet S. Walter(Leicester Royal Infirmary), John N. Allan(Cornell University), Jeffrey J. Pu(SUNY Upstate Medical University), Brittany McCall(Dartmouth–Hitchcock Medical Center), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Kavita Sail(AbbVie (United States)), Toby A. Eyre(Oxford University Hospitals NHS Trust), Paul M. Barr(University of Rochester Medical Center), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Maria Thadani‐Mulero(Roche (United Kingdom)), Arnon P. Kater(Amsterdam University Medical Centers), Beenish S. Manzoor(AbbVie (United States)), Michael Y. Choi(University of California San Diego), Kurt S. Bantilan(Memorial Sloan Kettering Cancer Center), Michelle Boyer(Amgen (United States)), Martin Šimkovič(Charles University), Stephen J. Schuster(Hospital of the University of Pennsylvania), John F. Seymour(The Royal Melbourne Hospital), Martin J.S. Dyer(University of Leicester), Marcus Lefebure(Peter MacCallum Cancer Centre), André Goy(Hackensack University Medical Center), Jae H. Park(Memorial Sloan Kettering Cancer Center), Manali Kamdar(University of Colorado Cancer Center), Juliana M.L. Biondo, Frederick Lansigan(Dartmouth College)
Cited by 57
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k